Capital Research Global Investors Lowers Holdings in ASP Isotopes Inc. $ASPI

Capital Research Global Investors decreased its position in ASP Isotopes Inc. (NASDAQ:ASPI) by 28.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,043,567 shares of the company’s stock after selling 824,495 shares during the period. Capital Research Global Investors’ holdings in ASP Isotopes were worth $19,659,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in ASP Isotopes during the 3rd quarter valued at about $34,000. Ameritas Investment Partners Inc. raised its holdings in ASP Isotopes by 41.2% in the second quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company’s stock worth $40,000 after buying an additional 1,600 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of ASP Isotopes by 84.9% in the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after buying an additional 2,548 shares in the last quarter. Close Asset Management Ltd purchased a new stake in shares of ASP Isotopes during the third quarter valued at approximately $72,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of ASP Isotopes by 96.7% during the second quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company’s stock valued at $80,000 after buying an additional 5,353 shares during the last quarter. 16.80% of the stock is owned by hedge funds and other institutional investors.

ASP Isotopes Price Performance

NASDAQ ASPI opened at $5.85 on Friday. The stock has a market capitalization of $648.41 million, a price-to-earnings ratio of -4.50 and a beta of 3.55. ASP Isotopes Inc. has a 1-year low of $3.86 and a 1-year high of $14.49. The company has a debt-to-equity ratio of 1.04, a current ratio of 6.14 and a quick ratio of 6.10. The business’s fifty day moving average price is $6.25 and its 200-day moving average price is $7.60.

Analyst Ratings Changes

Several brokerages recently weighed in on ASPI. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research report on Monday, December 29th. Canaccord Genuity Group reiterated a “buy” rating and set a $11.00 target price on shares of ASP Isotopes in a research note on Monday, November 24th. Finally, Cantor Fitzgerald initiated coverage on ASP Isotopes in a report on Thursday, December 4th. They issued an “overweight” rating and a $13.00 target price for the company. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $13.00.

Insiders Place Their Bets

In other ASP Isotopes news, COO Robert Ainscow sold 8,438 shares of the firm’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $5.44, for a total value of $45,902.72. Following the transaction, the chief operating officer directly owned 1,537,817 shares of the company’s stock, valued at approximately $8,365,724.48. This trade represents a 0.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Heather Kiessling sold 80,000 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $5.80, for a total value of $464,000.00. Following the sale, the chief financial officer owned 732,500 shares of the company’s stock, valued at approximately $4,248,500. This represents a 9.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 14.40% of the stock is currently owned by corporate insiders.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.